The Authors reply We greatly appreciate your useful comments on our paper about a case of adult onset mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome in a patient harboring a m.10158T>C mutation in the MT-ND3 gene (1).
al. proposed that mutation loads of >40% cause a complex I defect, with enzyme activity inversely related to the m.10158T>C mutation load (2) . However, a recent metaanalysis of patients carrying the m.10191T>C mutation, one of the pathogenic mutations of the MT-ND3 genedemonstrated that there was an unclear correlation between the mutation load and Complex I activity in the muscle and liver (7) . Thus, it is unclear whether there is a threshold effect or a linear relationship with the mutation load, or if the Complex I activity reflects pathological changes and clinical dysfunction.
The reason why patients who harbor the m.10158T>C mutation do not show muscle weakness or pathological findings suggestive of mitochondrial myopathy in spite of the high rate of heteroplasmy and the low Complex I activity associated with the mutation has not been established. However, the aim of this paper was to recommend mitochondrial DNA analyses using muscle biopsies in patients with suspected stroke-like episodes, even if the muscle pathology has a normal appearance.
